Success Stories: EB-1A Approved for a Formulation Scientist in Pennsylvania in the Field of Pharmaceutical Science
Client’s Testimonial:
Thanks for all your advice and wonderful work. I would be happy to recommend you on LinkedIn.
On January 26th, 2015, We Received Another EB1-A (Alien of Extraordinary Ability) Approval for a Formulation Scientist in the Field of Pharmaceutical Science (Approval Notice)
General Field: Pharmaceutical Science
Position at the Time of Case Filing: Formulation Scientist
Country of Origin: India
Service Center: Texas Service Center (TSC)
State of Residence at the Time of Filing: Pennsylvania
Approval Notice Date: January 26th, 2015
Processing Time: 7 months, 1 day
Case Summary:
For this case we worked with a pharmaceutical scientist from India with a specialized focus on increasing the efficiency of current drug therapies and developing ways in which there is little to no unintended uptake of the drugs in unaffected cells. His highly prolific career thus far had produced 21 peer-reviewed scientific articles, and he had been cited at least 842 times, primarily by independent researchers at prominent and leading institutions and organizations worldwide. This remarkable citation record clearly indicates the major significance of our client’s work. He had also reviewed at least 20 manuscripts for 10 or more distinctive, internationally-circulated journals. It was our goal to prove that our client qualified for classification as an Alien of Extraordinary Ability given that he sought to remain in the United States to continue work in the area of Pharmaceutical Science, and that his continued research would substantially and prospectively benefit the United States. An independent recommender affirmed the significance of our client’s research: “[Client’s] work outlines viable strategies for producing an immune response against HIV using HIV antigens bound to nanoparticles, providing the initial foundation for an effective HIV vaccine. This is a matter of international concern, as HIV/AIDS has claimed the lives of 36 million people worldwide since it was first reported in 1981, and an additional 2 million people are infected with HIV annually. These millions of lives provide a most compelling reason to continue to invest in research related to developing an effective vaccine, and [Client] is leading the way towards success in this endeavor. His initial findings have already taken the field by storm, as demonstrated by the inclusion of his articles on the topic in two of the top journals in pharmaceutical science.” With the proof and documentation that we provided, his case was approved in 7 months and 1 days.